By proceeding, you agree to our Terms of Use and Privacy Policy.
NEOsphere Biotechnologies is a pioneering proteomics company that creates value in strategic partnerships developing small molecule degraders as therapeutic agents against disease targets not yet exploited.
11-12 October 2022
The field of protein degradation has accelerated, and substantial interest is owed to its promise to therapeutically degrade proteins proving intractable to classical small molecule inhibition. As the field patiently waits for clinical trial readouts
Event Ended
Switzerland
Paid
Basel
24-26 January 2023
Built with biopharmaceutical industry insights, this in-person meeting will bring together KOLs to delve deep into the key remaining challenges when it comes to identifying, designing and developing the next generation of molecular glues and truly un
USA
Boston
11-13 April 2023
From discovery to clinical development, the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad
25-27 July 2023
Whilst still in infancy, the rise of multispecific drugs that drive induced proximity between otherwise disparate biological targets is shifting the drug discovery paradigm towards therapeutic interventions for previously undrugged, or hard-to-drug t
30-02 November 2023
The 6th Targeted Protein Degradation Summit is the premier event for professionals in the field of protein degradation drug development. Returning to Boston in 2023, this summit has established itself as the longest-standing and most comprehensive ga